ID   C1TC_HUMAN              Reviewed;         935 AA.
AC   P11586; B2R5Y2; G3V2B8; Q86VC9; Q9BVP5;
DT   01-OCT-1989, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   10-MAY-2017, entry version 199.
DE   RecName: Full=C-1-tetrahydrofolate synthase, cytoplasmic;
DE            Short=C1-THF synthase;
DE   Includes:
DE     RecName: Full=Methylenetetrahydrofolate dehydrogenase;
DE              EC=1.5.1.5;
DE   Includes:
DE     RecName: Full=Methenyltetrahydrofolate cyclohydrolase;
DE              EC=3.5.4.9;
DE   Includes:
DE     RecName: Full=Formyltetrahydrofolate synthetase;
DE              EC=6.3.4.3;
DE   Contains:
DE     RecName: Full=C-1-tetrahydrofolate synthase, cytoplasmic, N-terminally processed;
GN   Name=MTHFD1; Synonyms=MTHFC, MTHFD;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 2-31.
RC   TISSUE=Liver;
RX   PubMed=3053686;
RA   Hum D.W., Bell A.W., Rozen R., Mackenzie R.E.;
RT   "Primary structure of a human trifunctional enzyme. Isolation of a
RT   cDNA encoding methylenetetrahydrofolate dehydrogenase-
RT   methenyltetrahydrofolate cyclohydrolase-formyltetrahydrofolate
RT   synthetase.";
RL   J. Biol. Chem. 263:15946-15950(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT GLN-653.
RC   TISSUE=Amygdala;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12508121; DOI=10.1038/nature01348;
RA   Heilig R., Eckenberg R., Petit J.-L., Fonknechten N., Da Silva C.,
RA   Cattolico L., Levy M., Barbe V., De Berardinis V., Ureta-Vidal A.,
RA   Pelletier E., Vico V., Anthouard V., Rowen L., Madan A., Qin S.,
RA   Sun H., Du H., Pepin K., Artiguenave F., Robert C., Cruaud C.,
RA   Bruels T., Jaillon O., Friedlander L., Samson G., Brottier P.,
RA   Cure S., Segurens B., Aniere F., Samain S., Crespeau H., Abbasi N.,
RA   Aiach N., Boscus D., Dickhoff R., Dors M., Dubois I., Friedman C.,
RA   Gouyvenoux M., James R., Madan A., Mairey-Estrada B., Mangenot S.,
RA   Martins N., Menard M., Oztas S., Ratcliffe A., Shaffer T., Trask B.,
RA   Vacherie B., Bellemere C., Belser C., Besnard-Gonnet M.,
RA   Bartol-Mavel D., Boutard M., Briez-Silla S., Combette S.,
RA   Dufosse-Laurent V., Ferron C., Lechaplais C., Louesse C., Muselet D.,
RA   Magdelenat G., Pateau E., Petit E., Sirvain-Trukniewicz P., Trybou A.,
RA   Vega-Czarny N., Bataille E., Bluet E., Bordelais I., Dubois M.,
RA   Dumont C., Guerin T., Haffray S., Hammadi R., Muanga J., Pellouin V.,
RA   Robert D., Wunderle E., Gauguet G., Roy A., Sainte-Marthe L.,
RA   Verdier J., Verdier-Discala C., Hillier L.W., Fulton L., McPherson J.,
RA   Matsuda F., Wilson R., Scarpelli C., Gyapay G., Wincker P., Saurin W.,
RA   Quetier F., Waterston R., Hood L., Weissenbach J.;
RT   "The DNA sequence and analysis of human chromosome 14.";
RL   Nature 421:601-607(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT GLN-653.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS GLN-653 AND
RP   PHE-769.
RC   TISSUE=Brain, Eye, and Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PROTEIN SEQUENCE OF 2-17.
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A.,
RA   Thomas G.R., Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass
RT   spectrometric identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [7]
RP   PROTEIN SEQUENCE OF 2-17; 251-264; 314-324; 355-362; 596-616 AND
RP   722-733, CLEAVAGE OF INITIATOR METHIONINE, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   TISSUE=Foreskin fibroblast, and Prostatic carcinoma;
RA   Bienvenut W.V., Gao M., Leug H., Campbell A., Ozanne B.W.;
RL   Submitted (JUL-2009) to UniProtKB.
RN   [8]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [10]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.M111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C.,
RA   Meinnel T., Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [11]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-318; SER-413 AND
RP   SER-490, VARIANT [LARGE SCALE ANALYSIS] LYS-134, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 1-302.
RX   PubMed=9519408; DOI=10.1016/S0969-2126(98)00019-7;
RA   Allaire M., Li Y., Mackenzie R.E., Cygler M.;
RT   "The 3-D structure of a folate-dependent dehydrogenase/cyclohydrolase
RT   bifunctional enzyme at 1.5-A resolution.";
RL   Structure 6:173-182(1998).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 1-306 IN COMPLEX WITH NADP
RP   AND SUBSTRATE ANALOGS, SUBUNIT, AND MUTAGENESIS OF SER-49; TYR-52;
RP   LYS-56 AND CYS-147.
RX   PubMed=10828945; DOI=10.1021/bi992734y;
RA   Schmidt A., Wu H., MacKenzie R.E., Chen V.J., Bewly J.R., Ray J.E.,
RA   Toth J.E., Cygler M.;
RT   "Structures of three inhibitor complexes provide insight into the
RT   reaction mechanism of the human methylenetetrahydrofolate
RT   dehydrogenase/cyclohydrolase.";
RL   Biochemistry 39:6325-6335(2000).
RN   [16]
RP   INVOLVEMENT IN SUSCEPTIBILITY TO NTDFS, AND VARIANTS NTDFS HIS-293 AND
RP   GLN-653.
RX   PubMed=9611072;
RA   Hol F.A., van der Put N.M.J., Geurds M.P.A., Heil S.G.,
RA   Trijbels F.J.M., Hamel B.C.J., Mariman E.C.M., Blom H.J.;
RT   "Molecular genetic analysis of the gene encoding the trifunctional
RT   enzyme MTHFD (methylenetetrahydrofolate-dehydrogenase,
RT   methenyltetrahydrofolate-cyclohydrolase, formyltetrahydrofolate
RT   synthetase) in patients with neural tube defects.";
RL   Clin. Genet. 53:119-125(1998).
RN   [17]
RP   INVOLVEMENT IN SUSCEPTIBILITY TO NTDFS, VARIANT NTDFS GLN-653, AND
RP   VARIANT LYS-134.
RX   PubMed=12384833; DOI=10.1086/344213;
RA   Brody L.C., Conley M., Cox C., Kirke P.N., McKeever M.P., Mills J.L.,
RA   Molloy A.M., O'Leary V.B., Parle-McDermott A., Scott J.M.,
RA   Swanson D.A.;
RT   "A polymorphism, R653Q, in the trifunctional enzyme
RT   methylenetetrahydrofolate dehydrogenase/methenyltetrahydrofolate
RT   cyclohydrolase/formyltetrahydrofolate synthetase is a maternal genetic
RT   risk factor for neural tube defects: report of the Birth Defects
RT   Research Group.";
RL   Am. J. Hum. Genet. 71:1207-1215(2002).
RN   [18]
RP   INVOLVEMENT IN SUSCEPTIBILITY TO NTDFS, VARIANT NTDFS GLN-653, AND
RP   VARIANT LYS-134.
RX   PubMed=16552426; DOI=10.1038/sj.ejhg.5201603;
RA   Parle-McDermott A., Kirke P.N., Mills J.L., Molloy A.M., Cox C.,
RA   O'Leary V.B., Pangilinan F., Conley M., Cleary L., Brody L.C.,
RA   Scott J.M.;
RT   "Confirmation of the R653Q polymorphism of the trifunctional C1-
RT   synthase enzyme as a maternal risk for neural tube defects in the
RT   Irish population.";
RL   Eur. J. Hum. Genet. 14:768-772(2006).
RN   [19]
RP   VARIANT LYS-134, AND ASSOCIATION WITH COLORECTAL CANCER
RP   SUSCEPTIBILITY.
RX   PubMed=17000706; DOI=10.1093/hmg/ddl401;
RA   Webb E.L., Rudd M.F., Sellick G.S., El Galta R., Bethke L., Wood W.,
RA   Fletcher O., Penegar S., Withey L., Qureshi M., Johnson N.,
RA   Tomlinson I., Gray R., Peto J., Houlston R.S.;
RT   "Search for low penetrance alleles for colorectal cancer through a
RT   scan of 1467 non-synonymous SNPs in 2575 cases and 2707 controls with
RT   validation by kin-cohort analysis of 14 704 first-degree relatives.";
RL   Hum. Mol. Genet. 15:3263-3271(2006).
RN   [20]
RP   CHARACTERIZATION OF VARIANT GLN-653, AND ASSOCIATION WITH RISK OF
RP   CONGENITAL HEART DEFECTS.
RX   PubMed=18767138; DOI=10.1002/humu.20830;
RA   Christensen K.E., Rohlicek C.V., Andelfinger G.U., Michaud J.,
RA   Bigras J.-L., Richter A., Mackenzie R.E., Rozen R.;
RT   "The MTHFD1 p.Arg653Gln variant alters enzyme function and increases
RT   risk for congenital heart defects.";
RL   Hum. Mutat. 30:212-220(2009).
RN   [21]
RP   POSSIBLE INVOLVEMENT IN METABOLIC SYNDROMES, AND VARIANT CYS-173.
RX   PubMed=21813566; DOI=10.1136/jmedgenet-2011-100286;
RA   Watkins D., Schwartzentruber J.A., Ganesh J., Orange J.S.,
RA   Kaplan B.S., Nunez L.D., Majewski J., Rosenblatt D.S.;
RT   "Novel inborn error of folate metabolism: identification by exome
RT   capture and sequencing of mutations in the MTHFD1 gene in a single
RT   proband.";
RL   J. Med. Genet. 48:590-592(2011).
RN   [22]
RP   POSSIBLE INVOLVEMENT IN METABOLIC SYNDROMES, AND VARIANTS PHE-49 AND
RP   ILE-269.
RX   PubMed=25633902; DOI=10.1007/s10545-015-9810-3;
RA   Burda P., Kuster A., Hjalmarson O., Suormala T., Buerer C., Lutz S.,
RA   Roussey G., Christa L., Asin-Cayuela J., Kollberg G., Andersson B.A.,
RA   Watkins D., Rosenblatt D.S., Fowler B., Holme E., Froese D.S.,
RA   Baumgartner M.R.;
RT   "Characterization and review of MTHFD1 deficiency: four new patients,
RT   cellular delineation and response to folic and folinic acid
RT   treatment.";
RL   J. Inherit. Metab. Dis. 38:863-872(2015).
CC   -!- CATALYTIC ACTIVITY: 5,10-methylenetetrahydrofolate + NADP(+) =
CC       5,10-methenyltetrahydrofolate + NADPH.
CC   -!- CATALYTIC ACTIVITY: 5,10-methenyltetrahydrofolate + H(2)O = 10-
CC       formyltetrahydrofolate.
CC   -!- CATALYTIC ACTIVITY: ATP + formate + tetrahydrofolate = ADP +
CC       phosphate + 10-formyltetrahydrofolate.
CC   -!- PATHWAY: One-carbon metabolism; tetrahydrofolate interconversion.
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:10828945}.
CC   -!- INTERACTION:
CC       Q9WMX2:- (xeno); NbExp=3; IntAct=EBI-709638, EBI-710918;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm.
CC   -!- TISSUE SPECIFICITY: Ubiquitous.
CC   -!- DOMAIN: This trifunctional enzyme consists of two major domains:
CC       an N-terminal part containing the methylene-THF dehydrogenase and
CC       cyclohydrolase activities and a larger C-terminal part containing
CC       formyl-THF synthetase activity.
CC   -!- DISEASE: Neural tube defects, folate-sensitive (NTDFS)
CC       [MIM:601634]: The most common NTDs are open spina bifida
CC       (myelomeningocele) and anencephaly. {ECO:0000269|PubMed:12384833,
CC       ECO:0000269|PubMed:16552426, ECO:0000269|PubMed:9611072}.
CC       Note=Disease susceptibility is associated with variations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease
CC       characterized by malignant lesions arising from the inner wall of
CC       the large intestine (the colon) and the rectum. Genetic
CC       alterations are often associated with progression from
CC       premalignant lesion (adenoma) to invasive adenocarcinoma. Risk
CC       factors for cancer of the colon and rectum include colon polyps,
CC       long-standing ulcerative colitis, and genetic family history.
CC       Note=Disease susceptibility may be associated with variations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Note=MTHFD1 deficiency, due to mutation in this gene, can
CC       cause a metabolic syndrome with variable features including
CC       hyperhomocysteinemia, megaloblastic anemia, hemolytic uremic
CC       syndrome (HUS), severe combined immunodeficiency, microangiopathy
CC       and retinopathy. Symptoms improve after treatment with
CC       hydroxocobalamin, betaine and folinic acid.
CC       {ECO:0000269|PubMed:21813566, ECO:0000269|PubMed:25633902}.
CC   -!- SIMILARITY: In the N-terminal section; belongs to the
CC       tetrahydrofolate dehydrogenase/cyclohydrolase family.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: In the C-terminal section; belongs to the formate--
CC       tetrahydrofolate ligase family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; J04031; AAA59574.1; -; mRNA.
DR   EMBL; AK312361; BAG35279.1; -; mRNA.
DR   EMBL; AL122035; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471061; EAW80857.1; -; Genomic_DNA.
DR   EMBL; BC001014; AAH01014.2; -; mRNA.
DR   EMBL; BC009806; AAH09806.1; -; mRNA.
DR   EMBL; BC050420; AAH50420.1; -; mRNA.
DR   CCDS; CCDS9763.1; -.
DR   PIR; A31903; A31903.
DR   RefSeq; NP_005947.3; NM_005956.3.
DR   UniGene; Hs.652308; -.
DR   PDB; 1A4I; X-ray; 1.50 A; A/B=1-301.
DR   PDB; 1DIA; X-ray; 2.20 A; A/B=1-306.
DR   PDB; 1DIB; X-ray; 2.70 A; A/B=1-306.
DR   PDB; 1DIG; X-ray; 2.20 A; A/B=1-306.
DR   PDBsum; 1A4I; -.
DR   PDBsum; 1DIA; -.
DR   PDBsum; 1DIB; -.
DR   PDBsum; 1DIG; -.
DR   ProteinModelPortal; P11586; -.
DR   SMR; P11586; -.
DR   BioGrid; 110622; 73.
DR   DIP; DIP-33682N; -.
DR   IntAct; P11586; 15.
DR   MINT; MINT-5000922; -.
DR   STRING; 9606.ENSP00000450560; -.
DR   BindingDB; P11586; -.
DR   ChEMBL; CHEMBL2541; -.
DR   DrugBank; DB03461; 2'-Monophosphoadenosine 5'-Diphosphoribose.
DR   DrugBank; DB04322; LY249543.
DR   DrugBank; DB02358; LY374571.
DR   DrugBank; DB00157; NADH.
DR   DrugBank; DB00116; Tetrahydrofolic acid.
DR   iPTMnet; P11586; -.
DR   PhosphoSitePlus; P11586; -.
DR   SwissPalm; P11586; -.
DR   BioMuta; MTHFD1; -.
DR   DMDM; 115206; -.
DR   REPRODUCTION-2DPAGE; IPI00218342; -.
DR   SWISS-2DPAGE; P11586; -.
DR   EPD; P11586; -.
DR   MaxQB; P11586; -.
DR   PaxDb; P11586; -.
DR   PeptideAtlas; P11586; -.
DR   PRIDE; P11586; -.
DR   DNASU; 4522; -.
DR   Ensembl; ENST00000216605; ENSP00000216605; ENSG00000100714.
DR   Ensembl; ENST00000555709; ENSP00000450560; ENSG00000100714.
DR   GeneID; 4522; -.
DR   KEGG; hsa:4522; -.
DR   UCSC; uc001xhb.4; human.
DR   CTD; 4522; -.
DR   DisGeNET; 4522; -.
DR   GeneCards; MTHFD1; -.
DR   H-InvDB; HIX0011731; -.
DR   HGNC; HGNC:7432; MTHFD1.
DR   HPA; HPA000704; -.
DR   HPA; HPA001290; -.
DR   HPA; HPA015006; -.
DR   HPA; HPA050052; -.
DR   MalaCards; MTHFD1; -.
DR   MIM; 114500; phenotype.
DR   MIM; 172460; gene+phenotype.
DR   MIM; 601634; phenotype.
DR   neXtProt; NX_P11586; -.
DR   Orphanet; 268392; Cervical spina bifida aperta.
DR   Orphanet; 268762; Cervical spina bifida cystica.
DR   Orphanet; 268397; Cervicothoracic spina bifida aperta.
DR   Orphanet; 268766; Cervicothoracic spina bifida cystica.
DR   Orphanet; 268388; Lumbosacral spina bifida aperta.
DR   Orphanet; 268758; Lumbosacral spina bifida cystica.
DR   Orphanet; 268384; Thoracolumbosacral spina bifida aperta.
DR   Orphanet; 268752; Thoracolumbosacral spina bifida cystica.
DR   Orphanet; 268377; Total spina bifida aperta.
DR   Orphanet; 268748; Total spina bifida cystica.
DR   Orphanet; 268740; Upper thoracic spina bifida aperta.
DR   Orphanet; 268770; Upper thoracic spina bifida cystica.
DR   PharmGKB; PA31236; -.
DR   eggNOG; KOG4230; Eukaryota.
DR   eggNOG; COG0190; LUCA.
DR   eggNOG; COG2759; LUCA.
DR   HOVERGEN; HBG004916; -.
DR   InParanoid; P11586; -.
DR   KO; K00288; -.
DR   PhylomeDB; P11586; -.
DR   TreeFam; TF300623; -.
DR   BioCyc; MetaCyc:HS02138-MONOMER; -.
DR   BRENDA; 1.5.1.5; 2681.
DR   BRENDA; 3.5.4.9; 2681.
DR   BRENDA; 6.3.4.3; 2681.
DR   Reactome; R-HSA-196757; Metabolism of folate and pterines.
DR   UniPathway; UPA00193; -.
DR   ChiTaRS; MTHFD1; human.
DR   EvolutionaryTrace; P11586; -.
DR   GeneWiki; MTHFD1; -.
DR   GenomeRNAi; 4522; -.
DR   PRO; PR:P11586; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   Bgee; ENSG00000100714; -.
DR   CleanEx; HS_MTHFD1; -.
DR   ExpressionAtlas; P11586; baseline and differential.
DR   Genevisible; P11586; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; TAS:ProtInc.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004329; F:formate-tetrahydrofolate ligase activity; ISS:BHF-UCL.
DR   GO; GO:0004477; F:methenyltetrahydrofolate cyclohydrolase activity; IBA:GO_Central.
DR   GO; GO:0004487; F:methylenetetrahydrofolate dehydrogenase (NAD+) activity; ISS:BHF-UCL.
DR   GO; GO:0004488; F:methylenetetrahydrofolate dehydrogenase (NADP+) activity; IBA:GO_Central.
DR   GO; GO:0004486; F:methylenetetrahydrofolate dehydrogenase [NAD(P)+] activity; TAS:Reactome.
DR   GO; GO:0009257; P:10-formyltetrahydrofolate biosynthetic process; ISS:BHF-UCL.
DR   GO; GO:0048702; P:embryonic neurocranium morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0048703; P:embryonic viscerocranium morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0046655; P:folic acid metabolic process; TAS:Reactome.
DR   GO; GO:0007507; P:heart development; ISS:BHF-UCL.
DR   GO; GO:0000105; P:histidine biosynthetic process; IEA:UniProtKB-KW.
DR   GO; GO:0009086; P:methionine biosynthetic process; IMP:BHF-UCL.
DR   GO; GO:0006555; P:methionine metabolic process; ISS:BHF-UCL.
DR   GO; GO:0001843; P:neural tube closure; ISS:BHF-UCL.
DR   GO; GO:0001780; P:neutrophil homeostasis; IEA:Ensembl.
DR   GO; GO:0006730; P:one-carbon metabolic process; IMP:BHF-UCL.
DR   GO; GO:0009113; P:purine nucleobase biosynthetic process; IBA:GO_Central.
DR   GO; GO:0006164; P:purine nucleotide biosynthetic process; ISS:BHF-UCL.
DR   GO; GO:0009070; P:serine family amino acid biosynthetic process; IMP:BHF-UCL.
DR   GO; GO:0009069; P:serine family amino acid metabolic process; ISS:BHF-UCL.
DR   GO; GO:0061053; P:somite development; ISS:BHF-UCL.
DR   GO; GO:0035999; P:tetrahydrofolate interconversion; ISS:BHF-UCL.
DR   GO; GO:0019346; P:transsulfuration; IEA:Ensembl.
DR   CDD; cd00477; FTHFS; 1.
DR   HAMAP; MF_01543; FTHFS; 1.
DR   HAMAP; MF_01576; THF_DHG_CYH; 1.
DR   InterPro; IPR000559; Formate_THF_ligase.
DR   InterPro; IPR020628; Formate_THF_ligase_CS.
DR   InterPro; IPR016040; NAD(P)-bd_dom.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR000672; THF_DH/CycHdrlase.
DR   InterPro; IPR020630; THF_DH/CycHdrlase_cat_dom.
DR   InterPro; IPR020867; THF_DH/CycHdrlase_CS.
DR   InterPro; IPR020631; THF_DH/CycHdrlase_NAD-bd_dom.
DR   Pfam; PF01268; FTHFS; 1.
DR   Pfam; PF00763; THF_DHG_CYH; 1.
DR   Pfam; PF02882; THF_DHG_CYH_C; 1.
DR   PRINTS; PR00085; THFDHDRGNASE.
DR   SUPFAM; SSF51735; SSF51735; 1.
DR   SUPFAM; SSF52540; SSF52540; 2.
DR   PROSITE; PS00721; FTHFS_1; 1.
DR   PROSITE; PS00722; FTHFS_2; 1.
DR   PROSITE; PS00766; THF_DHG_CYH_1; 1.
DR   PROSITE; PS00767; THF_DHG_CYH_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Amino-acid biosynthesis; ATP-binding;
KW   Complete proteome; Cytoplasm; Direct protein sequencing;
KW   Disease mutation; Histidine biosynthesis; Hydrolase; Ligase;
KW   Methionine biosynthesis; Multifunctional enzyme; NADP;
KW   Nucleotide-binding; One-carbon metabolism; Oxidoreductase;
KW   Phosphoprotein; Polymorphism; Purine biosynthesis; Reference proteome.
FT   CHAIN         1    935       C-1-tetrahydrofolate synthase,
FT                                cytoplasmic.
FT                                /FTId=PRO_0000423280.
FT   INIT_MET      1      1       Removed; alternate.
FT                                {ECO:0000269|PubMed:12665801,
FT                                ECO:0000269|PubMed:3053686,
FT                                ECO:0000269|Ref.7}.
FT   CHAIN         2    935       C-1-tetrahydrofolate synthase,
FT                                cytoplasmic, N-terminally processed.
FT                                /FTId=PRO_0000199321.
FT   NP_BIND     172    174       NADP. {ECO:0000269|PubMed:10828945}.
FT   NP_BIND     380    387       ATP. {ECO:0000250}.
FT   REGION        2    305       Methylenetetrahydrofolate dehydrogenase
FT                                and cyclohydrolase.
FT   REGION       52     56       Substrate binding.
FT   REGION       99    101       Substrate binding.
FT   REGION      272    276       Substrate binding.
FT   REGION      306    935       Formyltetrahydrofolate synthetase.
FT   BINDING     197    197       NADP. {ECO:0000269|PubMed:10828945}.
FT   MOD_RES       1      1       N-acetylmethionine.
FT                                {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:22223895,
FT                                ECO:0000244|PubMed:22814378}.
FT   MOD_RES     318    318       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     413    413       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     490    490       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   VARIANT      49     49       S -> F (found in patients with MTFDH1
FT                                deficiency; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:25633902}.
FT                                /FTId=VAR_074075.
FT   VARIANT     134    134       R -> K (associated with increased risk of
FT                                colorectal cancer; dbSNP:rs1950902).
FT                                {ECO:0000244|PubMed:24275569,
FT                                ECO:0000269|PubMed:12384833,
FT                                ECO:0000269|PubMed:16552426,
FT                                ECO:0000269|PubMed:17000706}.
FT                                /FTId=VAR_016232.
FT   VARIANT     162    162       P -> L (in dbSNP:rs4902283).
FT                                /FTId=VAR_055458.
FT   VARIANT     173    173       R -> C (found in patients with MTFDH1
FT                                deficiency; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:21813566}.
FT                                /FTId=VAR_074076.
FT   VARIANT     269    269       T -> I (found in patients with MTFDH1
FT                                deficiency).
FT                                {ECO:0000269|PubMed:25633902}.
FT                                /FTId=VAR_074077.
FT   VARIANT     293    293       R -> H (in NTDFS; associated with disease
FT                                susceptibility; dbSNP:rs34181110).
FT                                /FTId=VAR_010241.
FT   VARIANT     653    653       R -> Q (in NTDFS; associated with disease
FT                                susceptibility; increases risk for
FT                                congenital heart defects; decreases
FT                                enzyme stability; dbSNP:rs2236225).
FT                                {ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:18767138,
FT                                ECO:0000269|PubMed:9611072,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_010251.
FT   VARIANT     761    761       T -> M (in dbSNP:rs10813).
FT                                /FTId=VAR_032789.
FT   VARIANT     769    769       L -> F (in dbSNP:rs17857382).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_032790.
FT   MUTAGEN      49     49       S->A: No effect on dehydrogenase and
FT                                cyclohydrolase activity. Strong increase
FT                                of Km for NADP.
FT                                {ECO:0000269|PubMed:10828945}.
FT   MUTAGEN      49     49       S->Q: Reduces dehydrogenase by 75% and
FT                                cyclohydrolase activity by 99%. No effect
FT                                on Km for NADP and for 5,10-
FT                                methenyltetrahydrofolate.
FT                                {ECO:0000269|PubMed:10828945}.
FT   MUTAGEN      52     52       Y->A,S: Reduces dehydrogenase activity by
FT                                99%. Reduces cyclohydrolase activity by
FT                                70%. No effect on Km for NADP and for
FT                                5,10-methenyltetrahydrofolate.
FT                                {ECO:0000269|PubMed:10828945}.
FT   MUTAGEN      52     52       Y->F: Slightly reduces dehydrogenase and
FT                                cyclohydrolase activity. Increase of Km
FT                                for NADP and for 5,10-
FT                                methenyltetrahydrofolate.
FT                                {ECO:0000269|PubMed:10828945}.
FT   MUTAGEN      56     56       K->A,I,S,T: Decreases dehydrogenase
FT                                activity over 90%. Loss of cyclohydrolase
FT                                activity. {ECO:0000269|PubMed:10828945}.
FT   MUTAGEN      56     56       K->E,M,Q: Moderate decrease of
FT                                dehydrogenase activity. Loss of
FT                                cyclohydrolase activity. Strong increase
FT                                of Km for NADP. Decrease of Km for 5,10-
FT                                methenyltetrahydrofolate.
FT                                {ECO:0000269|PubMed:10828945}.
FT   MUTAGEN      56     56       K->R: Reduces dehydrogenase and
FT                                cyclohydrolase activity by 99%. No effect
FT                                on Km for NADP and for 5,10-
FT                                methenyltetrahydrofolate.
FT                                {ECO:0000269|PubMed:10828945}.
FT   MUTAGEN     147    147       C->Q: Reduces dehydrogenase activity by
FT                                50% and cyclohydrolase activity by 87%.
FT                                {ECO:0000269|PubMed:10828945}.
FT   HELIX         9     30       {ECO:0000244|PDB:1A4I}.
FT   STRAND       37     44       {ECO:0000244|PDB:1A4I}.
FT   HELIX        47     63       {ECO:0000244|PDB:1A4I}.
FT   STRAND       66     72       {ECO:0000244|PDB:1A4I}.
FT   HELIX        78     90       {ECO:0000244|PDB:1A4I}.
FT   STRAND       96     99       {ECO:0000244|PDB:1A4I}.
FT   HELIX       111    116       {ECO:0000244|PDB:1A4I}.
FT   HELIX       120    122       {ECO:0000244|PDB:1A4I}.
FT   HELIX       129    136       {ECO:0000244|PDB:1A4I}.
FT   HELIX       147    157       {ECO:0000244|PDB:1A4I}.
FT   TURN        158    160       {ECO:0000244|PDB:1A4I}.
FT   STRAND      167    171       {ECO:0000244|PDB:1A4I}.
FT   TURN        175    177       {ECO:0000244|PDB:1A4I}.
FT   HELIX       178    187       {ECO:0000244|PDB:1A4I}.
FT   STRAND      191    195       {ECO:0000244|PDB:1A4I}.
FT   HELIX       202    206       {ECO:0000244|PDB:1A4I}.
FT   STRAND      210    214       {ECO:0000244|PDB:1A4I}.
FT   HELIX       224    226       {ECO:0000244|PDB:1A4I}.
FT   STRAND      232    235       {ECO:0000244|PDB:1A4I}.
FT   HELIX       258    261       {ECO:0000244|PDB:1A4I}.
FT   TURN        262    264       {ECO:0000244|PDB:1A4I}.
FT   STRAND      266    268       {ECO:0000244|PDB:1A4I}.
FT   STRAND      271    274       {ECO:0000244|PDB:1A4I}.
FT   HELIX       275    295       {ECO:0000244|PDB:1A4I}.
SQ   SEQUENCE   935 AA;  101559 MW;  29AE1C04B4922885 CRC64;
     MAPAEILNGK EISAQIRARL KNQVTQLKEQ VPGFTPRLAI LQVGNRDDSN LYINVKLKAA
     EEIGIKATHI KLPRTTTESE VMKYITSLNE DSTVHGFLVQ LPLDSENSIN TEEVINAIAP
     EKDVDGLTSI NAGRLARGDL NDCFIPCTPK GCLELIKETG VPIAGRHAVV VGRSKIVGAP
     MHDLLLWNNA TVTTCHSKTA HLDEEVNKGD ILVVATGQPE MVKGEWIKPG AIVIDCGINY
     VPDDKKPNGR KVVGDVAYDE AKERASFITP VPGGVGPMTV AMLMQSTVES AKRFLEKFKP
     GKWMIQYNNL NLKTPVPSDI DISRSCKPKP IGKLAREIGL LSEEVELYGE TKAKVLLSAL
     ERLKHRPDGK YVVVTGITPT PLGEGKSTTT IGLVQALGAH LYQNVFACVR QPSQGPTFGI
     KGGAAGGGYS QVIPMEEFNL HLTGDIHAIT AANNLVAAAI DARIFHELTQ TDKALFNRLV
     PSVNGVRRFS DIQIRRLKRL GIEKTDPTTL TDEEINRFAR LDIDPETITW QRVLDTNDRF
     LRKITIGQAP TEKGHTRTAQ FDISVASEIM AVLALTTSLE DMRERLGKMV VASSKKGEPV
     SAEDLGVSGA LTVLMKDAIK PNLMQTLEGT PVFVHAGPFA NIAHGNSSII ADRIALKLVG
     PEGFVVTEAG FGADIGMEKF FNIKCRYSGL CPHVVVLVAT VRALKMHGGG PTVTAGLPLP
     KAYIQENLEL VEKGFSNLKK QIENARMFGI PVVVAVNAFK TDTESELDLI SRLSREHGAF
     DAVKCTHWAE GGKGALALAQ AVQRAAQAPS SFQLLYDLKL PVEDKIRIIA QKIYGADDIE
     LLPEAQHKAE VYTKQGFGNL PICMAKTHLS LSHNPEQKGV PTGFILPIRD IRASVGAGFL
     YPLVGTMSTM PGLPTRPCFY DIDLDPETEQ VNGLF
//
